Diabetes risk assessment in adult population without diabetes employing continuous glucose monitoring: A novel approach

Research Projects

Organizational Units

Journal Issue

Abstract

Aims Time above range obtained through continuous glucose monitoring (CGM) is a useful marker for identifying individuals at higher risk of developing diabetes. We aimed to determine the optimal cutoff for the percentage of time glucose exceeds a threshold to predict diabetes onset. Methods Prospective observational study involving CGM in individuals without diabetes. Individuals who completed CGM and were not diagnosed with diabetes at baseline were followed for a median of 10.8 years. Results Among 513 individuals (median age: 46; range: 18–82), 42 developed diabetes during follow-up. Individuals who developed diabetes were older (median age [IQR]: 53 [45–63] vs. 45 [35–57] years; p < 0.001) and had a higher BMI (32.2 [28.9–35.2] vs. 26.8 [23.8–30.3] kg/m2; p < 0.001) compared to those who did not. The most significant differences between those who developed diabetes and those who did not were observed when we set a cutoff of ≥ 130 mg/dL for at least 10 % of monitoring time. Conclusions CGM provides highly useful information for predicting type 2 diabetes. In healthy individuals, exhibiting glucose levels at or above 130 mg/dL for over 10 % of the time over at least two monitoring days show a higher risk of developing type 2 diabetes.

Description

Bibliographic citation

Diabetes Research and Clinical Practice Volume 226, August 2025, 112286

Relation

Has part

Has version

Is based on

Is part of

Is referenced by

Is version of

Requires

Sponsors

This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/01069 and co-funded by the European Union; and the Network for Research on Chronicity, Primary Care, and Health Promotion, Instituto de Salud Carlos III (ISCIII), RD24/0005/0010, co-funded by the European Union. The Galician Innovation Agency-Competitive Benchmark Groups (GAIN-GRC/IN607A/2021/02/Xunta de Galicia) supported MA-S. This project was funded by the European Union (Programme for Research and Innovation, 2021-2027; Horizon Europe, EIC Pathfinder: 101161509-GLUCOTYPES). OL-B was granted by ISCIII Support Platforms for Clinical Research (PT23/00118/Co-funded by European Union).

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International